期刊文献+

卵巢透明细胞癌形态学及免疫组织化学表达与预后关系的研究

Correlation between morphology and immunohistochemical expressions and prognosis in clear cell carcinoma of ovary
下载PDF
导出
摘要 目的探讨卵巢透明细胞癌病理形态学、p53、Cyclin E、CD44_(V6)与预后的关系。方法收集解放军总医院1981-2002年间卵巢透明细胞癌手术切除病理标本28例,收集临床资料,判断临床分期;复习病理大体及镜下特点;对24例卵巢透明细胞癌患者行p53、Cyclin E与CD44_(V6)免疫组化染色;对全部28例卵巢透明细胞癌患者进行随访,随访时间为4~240个月。结果临床资料显示患者5年生存率为49.24%。其中Ⅰ期、Ⅱ期患者预后明显好于Ⅲ期患者。大体检查显示肿瘤最大直径<12cm的患者预后好于直径≥12cm的患者。显微镜检查显示合并子宫内膜异位症的患者预后好于不合并子宫内膜异位症的患者。细胞类型以透明细胞为主者型9例中死亡2例;以鞋钉细胞为主和透明细胞与鞋钉细胞共存者15例中死亡10例,两组生存时间差异有统计学意义。p53的表达与卵巢透明细胞癌患者生存时间没有相关性。24例卵巢透明细胞癌Cy-clinE均为阳性,阳性表达强弱与预后无明显相关性。24例卵巢透明细胞癌中13例CD44_(V6)阳性,CD44_(V6)表达组预后明显比非表达组差。结论肿瘤大、未合并子宫内膜异位、以鞋钉细胞为主预后较差;p53在卵巢透明细胞癌中表达率较低(25%),其表达与卵巢透明细胞癌患者生存时间没有相关性。cyclin E是卵巢透明细胞癌较理想的诊断标志物,在其病理诊断和鉴别诊断方面有较大价值。CD44_(V6)在卵巢CCC中的表达与预后密切关系,可以作为预测肿瘤转移潜能、评估预后的指标。 Objective To study the features of pathologic morphology and the expressions of p53,cyclin E,CD44V6in clear cell carcinoma,and their relationship with patients’ survival.Methods Twenty-four patients with clear cell carcinoma of ovary (CCCO)were studied by clinical data analysis,pathologic morphology and p53,CyclinE,CD44V6of immunohistochemical staining.The follow-up information was also analyzed.Results Among the 24 patients with CCCO the 5-year survival rate was 49.24%.The prognosis of patients in stage Ⅰ and Ⅱ was better than that of patients in stage Ⅲ(P12 cm(P=0.023).The prognosis of CCCO with endometriosis was better than that of CCCO without endometriosis(P=0.009).Two of the nine(22%)patients with predominant clear cells died and ten of the fifteen patients(66%) with hobnail cells and mixed clear-hobnail cells died.There was significant diffirenee between the two groups in survival time(P= 0.05),but not between the patieuts with and without the expression of p53(P=0.885).All the twenty-four cases of CCCO expressed cyclin E.There was significant difference in prognosis between the patients with and without expression of CD44V6,The prognosis of patients with positive CD44V6was worse than that of patients with negative CD44V6.(P=0.001).Conclusions The worse prognosis in patients with CCCO is correlated with tumor size,presence of endometriosis and the hobnail tumor cell type.There is no prognostic significance for expression of p53.Cyclin E is a better marker for pathologic diagnosis of CCCO.The expression of CD44V6 correlates with survival and prognosis.
出处 《武警医学》 CAS 2010年第2期135-138,142,共5页 Medical Journal of the Chinese People's Armed Police Force
关键词 卵巢透明细胞癌 病理学 免疫组织化学 预后随访 ovarian clear cell carcinoma pathology immunohistochemistry prognosis
  • 相关文献

参考文献11

  • 1马绍康,张宏图,吴令英,刘丽影.88例卵巢透明细胞癌临床及预后分析[J].中华肿瘤杂志,2007,29(10):784-788. 被引量:11
  • 2Masashi Takano,Toru Sugiyama,Nobuo Yaegashi,Mitsuaki Suzuki,Hiroshi Tsuda,Satoru Sagae,Yasuhiro Udagawa,Kazuo Kuzuya,Junzo Kigawa,Satoshi Takeuchi,Hitoshi Tsuda,Takuya Moriya,Yoshihiro Kikuchi.Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis[J]. International Journal of Clinical Oncology . 2007 (4)
  • 3Rodríguez-Rodríguez L,Sancho-Torres I.Clear cell carcinoma of the ovary:characterization of its CD44 iso-form repertoire. Gynecologic Oncology . 2000
  • 4Sugiyama T,Kamura T,Kigawa J,et al.Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer . 2000
  • 5Murta EF,Nomelini RS,Ferreira FA,et al.Ovarian clear cellcarcinoma associated with endometriosis:a case report withimmunohistochemical study. European Journal of Gynaecological Oncology . 2007
  • 6Kato N,Sasou S,Motoyam T.Expression of hepatocyte nuclear factor-1beta (HNF-1beta)in clear cell tumors and endometrio-sis of the ovary. Modern Pathology . 2006
  • 7Ho ES,Lai CR,Hsieh YT et al.p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecologic Oncology . 2001
  • 8Tavassoli FA,Devilee P.World Health Organization classification of tumors, pathology and genetics of tumors of the breast and female genital organs. . 2003
  • 9Session DR,Lee GS,Choi J,et al.Expression of cyclin E in gynecologic malignancies. Gynecologic Oncology . 1999
  • 10Tsuchiya A,Sakamoto M,Yasuda J,et al.Expression profilingin ovarian clear cell carcinoma:identification of hepatocyte nucle-ar factor-1 beta as a molecular marker and a possible moleculartarget for therapy of ovary clear cell carcinoma. American Journal of Pathology . 2003

二级参考文献15

  • 1陈晓军,丰有吉.CAP方案治疗卵巢上皮性癌178例远期疗效分析[J].复旦学报(医学版),2005,32(3):346-348. 被引量:4
  • 2Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer, 2006, 94: 1369-1374.
  • 3Kennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol, 1989, 32 : 342-349.
  • 4Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary:a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer, 2000, 88 : 2584-2589.
  • 5Crozier MA, Copeland LJ, Silva EG, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol, 1989, 35:199-203.
  • 6Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol, 1998, 70: 255-258.
  • 7Komiyama S, Aoki D, Tominaga E, et al. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. Gynecol Oncol, 1999, 72 : 342-346.
  • 8Goff BA, Sainz dela CuestaR, Muntz HG, et al. Clear cell carcinoma of the ovary : a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage Ⅲ disease. Gynecol Oncol, 1996, 60: 412-417.
  • 9Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol, 1991, 9: 1138-1150.
  • 10Ho CM, Chien TY, Shih BY, et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage Ⅰ ovarian clear cell carcinoma. Gynecol Oncol, 2003, 88:394-399.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部